Product Information
EMTRICITABINE-TENOFOVIR DISOPROXIL FUMARATE 200-300 MG TAB is a generic product labeled by Teva Pharmaceuticals USA Inc., priced at $0.5290 per EA under NDC 00093770456. Its NADAC has been published 294 times since Feb 17, 2021.
FDA first approved this application on Jun 8, 2017. Its Orange Book therapeutic-equivalence code is AB — FDA rates it therapeutically equivalent to (substitutable for) its reference product.
EMTRICITABINE-TENOFOVIR DISOPROXIL FUMARATE 200-300 MG TAB
Emtricitabine and Tenofovir Disoproxil FumarateStrength
200; 300 mg/1; mg/1
Manufacturer
Teva Pharmaceuticals USA Inc.NDC
00093770456
Classification
Generic
Dosage Form
TABLET, FILM COATED
Route
ORAL
Effective Date
9/23/2026
Active Ingredients
EMTRICITABINE; TENOFOVIR DISOPROXIL FUMARATEApproval Type
Generic (ANDA)
FDA Application
ANDA090894FDA Approved
6/8/2017
TE Code
AB
On Market Since
1/20/2021
Pharmacological Classes
Price Statistics
The NADAC for EMTRICITABINE-TENOFOVIR DISOPROXIL FUMARATE 200-300 MG TAB has been published 294 times since Feb 17, 2021, and over the history we have for it it has declined 98.8%. The table below summarizes its recorded NADAC range and movement.
| Current price | $0.5290 per EA |
|---|---|
| All-time high | $45.9367 (Apr 14, 2021) |
| All-time low | $0.4258 (May 22, 2024) |
| 52-week high | $0.5867 |
| 52-week low | $0.4508 |
| Median price | $0.5846 |
| Average price | $2.9114 |
| Largest weekly change | -97.1% (Jun 2, 2021) |
| Weeks tracked | 294 |
| Tracking since | Feb 17, 2021 |
Generic Alternatives
The matcher finds 6 manufacturers offering a NADAC-published product with this drug's active ingredient and strength in a comparable dosage form (cheapest from each manufacturer, up to 10 shown below). Switching to the cheapest would cut per-unit acquisition cost by roughly 15% at current NADAC. These are candidates to verify clinically, not guaranteed substitutes — see our generic drug prices guide.
Related Drugs
Same classification
Continue researching this drug
Use these direct paths to move from a single NDC into the surrounding market, manufacturer, class, and trend context.
Manufacturer
Teva Pharmaceuticals USA Inc. manufacturer profile
See the full portfolio, pricing trend, and other products from this labeler.
Drug market
Emtricitabine and Tenofovir Disoproxil Fumarate market comparison
Compare this molecule across participating manufacturers and inspect the broader market price spread.
Therapeutic class
Hepatitis B Virus Nucleoside Analog Reverse Transcriptase Inhibitor class view
See how this drug behaves alongside other products in the same FDA pharmacologic class.
Trend hub
Latest market trends
Zoom back out to the weekly mover view and compare this NDC with the rest of the current NADAC release.
Guide
Understanding NADAC pricing
Use the explainer when you need context on how CMS publishes NADAC and how to interpret the number on this page.
Frequently asked questions
What is the NADAC price of EMTRICITABINE-TENOFOVIR DISOPROXIL FUMARATE 200-300 MG TAB?
The current National Average Drug Acquisition Cost (NADAC) for EMTRICITABINE-TENOFOVIR DISOPROXIL FUMARATE 200-300 MG TAB, manufactured by Teva Pharmaceuticals USA Inc., is $0.5290 per EA (NDC 00093770456), effective Sep 30, 2026.
How has the price of EMTRICITABINE-TENOFOVIR DISOPROXIL FUMARATE 200-300 MG TAB changed over time?
Over the history we have for it, the NADAC for EMTRICITABINE-TENOFOVIR DISOPROXIL FUMARATE 200-300 MG TAB has declined 98.8%. It has been tracked across 294 weekly CMS publications since Feb 17, 2021.
What are the highest and lowest recorded NADAC prices for EMTRICITABINE-TENOFOVIR DISOPROXIL FUMARATE 200-300 MG TAB?
Since Feb 17, 2021, the NADAC for EMTRICITABINE-TENOFOVIR DISOPROXIL FUMARATE 200-300 MG TAB has ranged from a low of $0.4258 (May 22, 2024) to a high of $45.9367 (Apr 14, 2021), with a median of $0.5846 per EA.
Are there cheaper alternatives to EMTRICITABINE-TENOFOVIR DISOPROXIL FUMARATE 200-300 MG TAB?
Yes. 6 manufacturers publish a NADAC-priced product with the same active ingredient and strength in a comparable dosage form. The lowest-priced option, EMTRICITABINE-TENOFOVIR DISOPROXIL FUMARATE 200-300 MG TAB, is $0.4508 per EA — about 15% below EMTRICITABINE-TENOFOVIR DISOPROXIL FUMARATE 200-300 MG TAB.
Who manufactures EMTRICITABINE-TENOFOVIR DISOPROXIL FUMARATE 200-300 MG TAB?
EMTRICITABINE-TENOFOVIR DISOPROXIL FUMARATE 200-300 MG TAB (NDC 00093770456) is labeled by Teva Pharmaceuticals USA Inc., and CMS classifies it as a generic product.